CSL Ltd Stock
Price
Target price
€81.56
€81.56
0.410%
0.33
0.410%
-
06.08.26 / Tradegate
WKN: 890952 / Symbol: CMXHF / Name: CSL / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of CSL Ltd in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CSL Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CSL Ltd | 0.410% | 5.334% | 8.285% | -45.886% | -17.815% | -48.051% | -56.184% |
| Grifols SA | -1.280% | -2.958% | 11.669% | -26.231% | -12.117% | - | - |
| Grifols S.A. | -1.220% | -2.546% | 12.149% | -20.212% | -7.140% | -21.357% | -51.273% |
| IQVIA Holdings Inc. | -1.470% | -2.230% | 11.993% | 32.479% | 4.454% | 2.282% | -3.861% |
News
Arcturus Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Arcturus Therapeutics Holdings Inc.? Here are five stocks we like better.
- ARCT-032 cystic fibrosis study remains on track: Phase II enrollment is active in the U.S
Carlisle Companies: A Strong Contender in the Building Products Sector
Explore the exciting world of Carlisle Companies (NYSE: CSL) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into
